FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR HBV Infection Associated with Increased Risk of Primary Extrahepatic Malignancies May 23, 2022 “Solid Stress” Keeps Immune System from Killing Off Cancer Cells in... July 21, 2021 Can mRNA Vaccines Help Treat Cancer? January 20, 2022 Mom Who Fought Breast Cancer While Pregnant Describes The Benefits Of... January 20, 2020 Load more HOT NEWS Learning to Advocate for Yourself – An Important Skill! FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... Satisfying Snacks Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients...
